Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$0.96
EPS est.
$0.64
EPS surprise
+50.71%
1-day move
+7.70%
Indivior's strong earnings per share performance significantly exceeded expectations, leading to a 7.7% increase in stock price. However, revenue figures were not disclosed, leaving some uncertainty about overall financial health. Investors may view the EPS beat as a positive sign for the company's profitability moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.96 | $0.66 | +50.71% |
| Revenue | N/A | $273M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative treatments for addiction and related disorders. With a market cap of $4 billion, it plays a crucial role in addressing public health issues, particularly in the area of opioid dependence.
Last quarter
In Q4-2025, Indivior reported an EPS of $0.82, significantly beating the estimate of $0.65. The stock reacted positively, increasing by 0.24% the following day.
EPS beat streak
5Q
EPS beat rate
100%
Avg EPS surprise
+58.43%
Avg 1-day reaction
+6.57%
Analysts expect Indivior to continue its strong performance with an EPS of $0.66 and revenue of $273 million. The company has a history of beating earnings expectations.
Bull case
If Indivior maintains its trend of exceeding EPS estimates, it could see a strong stock price increase, especially given the positive market sentiment.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility.
Key metrics to watch
EPS
$0.66Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue
$273MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $0.66?
A continued trend of beating EPS estimates could reinforce investor confidence and drive the stock price higher.
Q2
What are the revenue expectations for the upcoming quarter?
Revenue performance will indicate market demand for Indivior's products and could significantly influence stock performance.
—
Est. EPS
$1.21
Est. Rev
$34.9B
Impl. Move
±5.2%
Why consensus could be wrong
The consensus may be underestimating the potential for Indivior to exceed EPS expectations based on its recent performance trends.
Supporting evidence
Indivior has consistently beaten EPS estimates in the last three quarters, suggesting strong operational performance.
The options market is pricing in a larger move than historical averages, indicating expectations of volatility that may not be justified.
The company's focus on addiction treatments aligns with increasing public health priorities, potentially driving higher demand.
Key risk
If EPS comes in below $0.61, it would challenge the current bullish sentiment and raise concerns about the company's growth.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will either reinforce the company's strong growth narrative or raise red flags about its future prospects.
Bull confirmed if
An EPS of $0.70 or higher would confirm the bullish outlook and indicate strong operational performance.
Bear confirmed if
An EPS below $0.61 would validate the bearish case and raise concerns about the company's growth trajectory.
What the market is pricing for the move.
Implied Move
±19.85%
Historical Avg
±9.2%
The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.
Options are pricing ±19.8% while INDV has averaged ±9.2% over the last 5 prints — setup is pricing rich.
ATM IV
1.0%
30d HV
41.9%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 7 of 23 (30%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
102.97%
of float
Insider
1.80%
of float
Holders
457
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
18,709,432 sh · $676.0M
15.85%
0.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Indivior beats expectations, history suggests the stock could rise by an average of 10.58%, confirming its strong growth narrative.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.
Miss
A miss could lead to a significant decline, with historical data suggesting an average drop of around 10.58%.
The lines on the call that would change the story.
Vanguard Portfolio Management LLC
7,572,287 sh · $273.6M
6.42%
-4.0%
Oaktree Capital Management LP
6,127,212 sh · $221.4M
5.19%
-12.3%
Vanguard Capital Management LLC
5,495,486 sh · $198.6M
4.66%
-1.6%
State Street Corporation
4,992,071 sh · $180.4M
4.23%
1.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.